Evidence map›Paper›PMID 36416313›Full record

ArticleHua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology2022

The immune checkpoint inhibitors treatment of head and neck squamous cell carcinoma: an expert consensus.

Lei Liu, Zhongzheng Xiang, Yi Li, Wei Guo, Kai Yang, Jun Wang, Zhijun Sun, Guoxin Ren, Jianguo Zhang, Moyi Sun and 4 more

Open access · greenAbstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Lei LiuDept. of Head and Neck Oncology, West China Hospital of Sichuan University, Chengdu 610041, China.
Zhongzheng XiangDept. of Head and Neck Oncology, West China Hospital of Sichuan University, Chengdu 610041, China.
Yi LiState Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases & Dept. of Head and Neck Oncology, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China.
Wei GuoDept. of Oral and Maxillofacial-head and Neck Oncology, Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai 200011, China.
Kai YangDept. of Oral and Maxillofacial Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
Jun WangDept. of Head and Neck Oncology, West China Hospital of Sichuan University, Chengdu 610041, China.
Zhijun SunDept. of Oral and Maxillofacial Surgery, School & Hospital of Stomatology, Wuhan University, Wuhan 430079, China.
Guoxin RenDept. of Oral and Maxillofacial-head and Neck Oncology, Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai 200011, China.
Jianguo ZhangDept. of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology, Beijing 100081, China.
Moyi SunDept. of Oral and Maxillofacial Surgery, Hospital of Stomatology, Air Force Medical University, Xi'an 710032, China.
Wei RanDept. of Oral and Maxillofacial Surgery, First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China.
Guilin HuangDept. of Oral and Maxillofacial Surgery, Stomatological Hospital, Zunyi Medical University, Zunyi 563000, China.
Zhangui TangDept. of Oral and Maxillofacial Surgery, Xiangya School of Stomatology, Central South University, Changsha 410000, China.
Longjiang LiState Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases & Dept. of Head and Neck Oncology, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China.
Sichuan University · CNState Key Laboratory of Oral Diseases

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint inhibitors (ICIs) present significant efficacy in the treatment of malignant tumors, and they have been approved as the first-line of treatment for various cancers. Pembrolizumab monotherapy or combined with chemotherapy has been recommended by domestic and foreign guidelines for the first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma. Although ICIs represent a milestone in the treatment of head and neck squamous cell carcinoma, potential problems still need to be addressed, such as the selection of the efficacy predictors for ICIs, the evaluation of the tumor response to ICIs, and the treatment of immune hyperprogression and immune-related adverse events. Therefore, to form a relatively unified understanding of ICIs treatment for head and neck squamous cell carcinoma, we integrated the clinical experience of multi-disciplinary experts of head and neck cancers on the basis of current clinical hot issues and finally developed this consensus.

Indexed as

Head and Neck NeoplasmsImmune Checkpoint InhibitorsConsensusHumansNeoplasm Recurrence, LocalSquamous Cell Carcinoma of Head and NeckImmune Checkpoint Inhibitorsexpert consensushead and neck squamous cell carcinomaimmune checkpoint inhibitorsimmunotherapy

Identifiers

PMID36416313
PMCPMC9763948
OpenAlexW4310336517

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.